Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 23;12(23):7270.
doi: 10.3390/jcm12237270.

On-Demand ICS + FABA Combinations in 6-11-Year-Old Children

Elsy M Navarrete-Rodríguez  1 , Blanca E Del-Rio-Navarro  1 , Désirée Larenas-Linnemann  2 , Jose A Castro-Rodriguez  3
Affiliations
Review

On-Demand ICS + FABA Combinations in 6-11-Year-Old Children

Elsy M Navarrete-Rodríguez et al. J Clin Med. .

Abstract

In recent years, some new concepts have been added to asthma treatment such as "anti-inflammatory reliever" (β2-agonist use associated to an inhaled corticosteroid (ICS) as a reliever treatment) that combines the benefits of both therapies and provides short- and long-term benefits for treatment in asthma patients. Robust evidence has been presented in patients over 12 years, and the main changes in the international guidelines for asthma treatment were originally made in this age group. However, a few suggestions have been added to treatments in younger patients, in part because of the scarce evidence that exists in this group. We aim to analyze the information regarding the utilization of ICS + fast-acting beta-agonist (FABA) combination in children between 6 and 11 years. Although up until today only three published trials exist (two studies use beclomethasone + albuterol and one study uses budesonide + formoterol), they provide significant information on the benefits of ICS + FABA use in this population.

Keywords: anti-inflammatory rescue therapy; asthma treatment; fast-acting beta-agonist; school children.

PubMed Disclaimer

Conflict of interest statement

Elsy M. Navarrete-Rodriguez receives speaking support and advice from Sanofi, AstraZeneca, GSK, Pfizer. Blanca E. del-Rio-Navarro receives speaking support and advice from Sanofi, Grunenthal. Désirée Larenas Linnemann receives speaking support and advice from Allakos, Armstrong, AstraZeneca, DBV Technologies, Grunenthal, GSK, Mylan, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer; and research grants from Sanofi, AstraZeneca, Novartis, Circassia, UCB, GSK, TEVA, Purina Institute. Désirée E.S. Larenas-Linnemann reports personal fees from ALK, AstraZeneca national and global, Bayer, Chiesi, Grunenthal, Grin, GSK national and global, Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Carnot, grants from Abbvie, Bayer, Lilly, Sanofi, AstraZeneca, Pfizer, Novartis, Circassia, UCB, GSK., outside the submitted work. She is coordinator of the immunotherapy committee of CMICA and general coordinator of ten national guidelines in the field of allergy, asthma, and immunotherapy. Jose A. Castro-Rodriguez receives speaking support and advice from AstraZeneca, Cassará, Europharma, GSK, and Sanofi.

Figures

Figure 1
Figure 1
Summary of studies for the use of ICS + bronchodilator in children under 18 years of age [13,14,15,16]. Abbreviations: ND, not done; FEV1, forced expiratory volume in first second; ICS, inhaled corticosteroid; PEF, peak expiratory flow; SABA, short-acting β2-agonist; FENO, fractional exhaled nitric oxide; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; BDP, beclomethasone dipropionate; BID, twice daily; QD, once daily.
Figure 1
Figure 1
Summary of studies for the use of ICS + bronchodilator in children under 18 years of age [13,14,15,16]. Abbreviations: ND, not done; FEV1, forced expiratory volume in first second; ICS, inhaled corticosteroid; PEF, peak expiratory flow; SABA, short-acting β2-agonist; FENO, fractional exhaled nitric oxide; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; BDP, beclomethasone dipropionate; BID, twice daily; QD, once daily.
Figure 1
Figure 1
Summary of studies for the use of ICS + bronchodilator in children under 18 years of age [13,14,15,16]. Abbreviations: ND, not done; FEV1, forced expiratory volume in first second; ICS, inhaled corticosteroid; PEF, peak expiratory flow; SABA, short-acting β2-agonist; FENO, fractional exhaled nitric oxide; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; BDP, beclomethasone dipropionate; BID, twice daily; QD, once daily.
See this image and copyright information in PMC

References

    1. GINA Committee . Global Strategy for Asthma Management and Prevention 2023 Update. Global Initiative for Asthma; Fontana, WI, USA: 2023.
    1. GUÍA ESPAÑOLA PARA EL MANEJO DEL ASMA. [(accessed on 1 July 2023)]. Available online: www.gemasma.com.
    1. Stein S.W., Thiel C.G. The History of Therapeutic Aerosols: A Chronological Review. J. Aerosol Med. Pulm. Drug Deliv. 2017;30:20–41. doi: 10.1089/jamp.2016.1297. - DOI - PMC - PubMed
    1. Inman W.H., Adelstein A.M. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet. 1969;2:7615. doi: 10.1016/S0140-6736(69)90051-8. - DOI - PubMed
    1. British Thoracic Society BTS/SIGN British Guideline on the Management of Asthma. Asthma. 2019. [(accessed on 1 July 2023)]. Available online: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/

LinkOut - more resources